In conclusion, we demonstrated that MT2A could be considered as a predictive biomarker of the efficacy of chemotherapy for patients with osteosarcoma, and as a potential therapeutic target to develop novel treatment strategy to prevent or de-escalate chemo-resistance in osteosarcoma. This evidence concerns the gene MT2A and osteosarcoma.